Slide 1: Sera Prognostics Update
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Sera Prognostics Update September 25, 2023
Slide 2: Disclaimer
Disclaimer ©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. This presentation contains forward-looking statements that involve substantial risks and uncertainties. All st
Slide 3: Our Vision
Sera Prognostics aims to be a global leader in high-value women’s health diagnostics, delivering pivotal pregnancy information to improve the health of women and newborns, and to simultaneously improve the economics of healthcare Our Vision ©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, S
Slide 4: Who We Are – The Pregnancy Company
Who We Are – The Pregnancy Company® ©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. • Proteomics and bioinformatics platform company focusing on creating valuable pregna
Slide 5: Extensible Proprietary Bioinformatics and Proteomics Platform
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Extensible Proprietary Bioinformatics and Proteomics Platform
Slide 6: Sera's Robust Biomarker Pregnancy Pipeline
Predictor Est. U.S. Prevalence in Pregnancy Discovery Verification Validation Commercialized Upcoming Expected Milestones and Anticipated Timing PreTRM® Test for Risk of Preterm Birth 10% • Publications of additional clinical and economic outcome studies (2024-2025) • PRIME: interim in late 2023; fi
Slide 7: U.S. Preterm Birth Crisis and Prevalence
U.S. Preterm Birth Crisis ©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Prevalence • Preterm birth (PTB) is defined as any delivery occurring before 37 weeks’ gestatio
Slide 8: Economic Benefit of a Test Enabling Effective Intervention
- 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000 $- $100 $200 $300 $400 $500 $600 $700 24 25 26 27 28 29 30 31 32 33 34 35 36 A n n u a l N u m b e r o f B ir th s A ve ra g e C o s t P e r P T B ( th o u s a n d s ) Gestational Age at Birth (weeks) Number PTB Ave Cost/PTB of Costs Occu
Slide 9: PAPR & TREETOP Studies: Validating Biomarker Signature for Preterm Birth Risk
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. PAPR Study • Groundbreaking prediction validation study • 5,501 patients, 11 U.S. sites • Validated proprietary biomarker
Slide 10: Clinical utility study at Intermountain Healthcare
• Assessed benefit of identifying higher risk pregnancies coupled with earlier proactive interventions vs. standard practice • 1,208 patients enrolled,, conducted at Intermountain Healthcare in Utah • Examined outcomes of clinical and economic importance, including NICU length of stay, total hospita
Slide 11: PRIME Study: Elevance Health and Sera Collaborate
• Collaboration with Elevance based on health economic analysis from HealthCore • Multicenter prospective randomized controlled study within Elevance network • Up to 6,500 participants in approx. 15 U.S. sites • Evaluates benefit of PreTRM identification of higher risk pregnancies coupled with proac
Slide 12: Anthem Claims Data Results
Anthem Claims Data • Analysis of >40,000 mothers and babies within commercially insured Elevance membership – Evaluated screening with PreTRM along with proactive interventions given to PreTRM-higher risk patients vs. standard care – Demonstrated robust clinical and economic impacts of the PreTRM te
Slide 13: Near-term Execution: Accelerate PreTRM Adoption and Revenue
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Near-term Execution Accelerate PreTRM Adoption and Revenue
Slide 14: Distinct Levers to Near-Term Revenue
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. 1 Reengaging institutions with the data • PREVENT Sub-analysis • AVERT PRETERM TRIAL • PRIME • Vietnam Study • RWEs Pilot
Slide 15: Adding outcome evidence to our data story
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Adding outcome evidence to our data story
Slide 16: A strong foundation of evidence
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. CONFIDENTIAL A strong foundation of evidence CLINICAL STUDIES ANALYTICAL VALIDATION CLINICAL VALIDATION CLINICAL UTILITY
Slide 17: Building on the foundation with new clinical utility evidence
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. CONFIDENTIAL Building on the foundation with new clinical utility evidence CLINICAL STUDIES ANALYTICAL VALIDATION CLINICA
Slide 18: AVERT PRETERM TRIAL
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. AVERT PRETERM TRIAL
Slide 19: Severe morbidity and mortality rates were significantly reduced
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Severe morbidity and mortality rates were significantly reduced *Severe neonatal morbidity and mortality are defined as N
Slide 20: Gestational age at birth was increased for those at risk of earliest delivery
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Gestational age at birth was increased for those at risk of earliest delivery Control Arm (Standard of Care) N=155 Mean G
Slide 21: Time spent in the hospital reduced for those at risk of earliest delivery
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. P ro p o rt io n o f N e o n a te s R e m a in in g i n t h e H o sp it a l Neonatal Hospital Length of Stay (days) Neona
Slide 22: Neonatal Hospital Length of Stay
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Neonatal Hospital Length of Stay P ro p o rt io n o f N e o n a te s R e m a in in g i n t h e H o s p it a l Length of S
Slide 23: PREVENT-PTB Study – Sub-analysis
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. PREVENT-PTB Study – Sub-analysis
Slide 24: Impacts of care management for patients screened with PreTRM
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Impacts of care management for patients screened with the PreTRM® Test was demonstrated in a recent publication Secondary
Slide 25: Significant reductions in NICU length of stay
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Subgroup defined by the earliest decile of each group, i.e., the 10% of subjects with the lowest Gabirth From the PREVENT
Slide 26: Significant improvements in gestational age at birth
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Lorem ipsum P ro p o rt io n o f P a ti e n ts R e m a in in g U n d e li v e re d Gestational Age (weeks) Gestational Ag
Slide 27: Care Coordination Pilot
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Care Coordination Pilot
Slide 28: Care Coordination
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. CONFIDENTIAL Piloting offering to support higher risk patients by coordinating with physician's care • Addresses a hurdle
Slide 29: Real-world Evidence Development
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Real-world Evidence Development
Slide 30: Real-World Evidence Implementation Programs
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are registered trademarks of Sera Prognostics, Inc. in the United States. CONFIDENTIAL Real-World Evidence Implementation Programs KEY OPINION LEADER MFM CHAMPION Objective: Expand PreTRM clinical utility data
Slide 31: Medium-term Vision: Building a multi-product platform
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Medium-term Vision Building a multi-product platform
Slide 32: Product Portfolio: Time To Birth (TTB)
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. CONFIDENTIAL Product Portfolio: Time To Birth (TTB) Intended Use To provide a more accurate estimate of when a mother’s b
Slide 33: Product Portfolio: Pregnancy Risk Prediction Panel
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. CONFIDENTIAL Product Portfolio: Pregnancy Risk Prediction Panel Intended Use To provide a woman and her physician a risk
Slide 34: Long-term Vision: A Bigger Picture
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Long-term Vision A Bigger Picture
Slide 35: Sera is more than just PreTRM
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Today 2023 2024 2025 2026 PreTRM Test Time to Birth Test Pregnancy Risk Prediction Panel Predictive Analytics Product Ser
Slide 36: Data As An Asset
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are registered trademarks of Sera Prognostics, Inc. in the United States. As many as 30% of pregnancies are affected by various complications (i.e., a high-risk pregnancy), including: preterm birth, preeclamps
Slide 37: International Expansion
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are registered trademarks of Sera Prognostics, Inc. in the United States. Currently exploring opportunities with partners in: International Expansion EUROPE ASIA MIDDLE EAST
Slide 38: Key Upcoming Events
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Key Upcoming Events
Slide 39: Upcoming Events - next 6 months
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. CONFIDENTIAL Upcoming Events - next 6 months Date Event September 26, 2023 Cantor Global Healthcare Conference November 8
Slide 40: Questions?
©2023 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. 1 Questions?